May 20, 2015—In a recent interview, Exalenz Bioscience CEO Larry Cohen discussed his company’s innovations in testing for H. Pylori and clinically significant portal hypertension with its BreathID test. Read it.
May 20, 2015—In a recent interview, Exalenz Bioscience CEO Larry Cohen discussed his company’s innovations in testing for H. Pylori and clinically significant portal hypertension with its BreathID test. Read it.